Uncategorized

Moderna’s flu candidate sails through FDA advisory committee in unanimous votes

Published

on

As Moderna reshapes itself in the wake of the pandemic, the company on Thursday passed a key milestone in its bid to expand the reach of its mRNA platform to the massive influenza vaccination market.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version